SB 1606 would require health carriers and health benefit plans in Missouri, for policies delivered, issued, renewed, or continued on or after January 1, 2027, to cover treatment for obesity and severe obesity, as well as obesity-related diseases and ailments, for individuals ages 2 through 20. Covered services would include intensive health behavior and lifestyle treatment, pharmacotherapy, and metabolic and bariatric surgery, so long as the treatment follows clinical practice guidelines from the American Academy of Pediatrics and the American Society for Metabolic and Bariatric Surgery Pediatric Committee.
The bill also limits cost-sharing by prohibiting these required services from being subject to a higher deductible or copayment than other covered health care services under the plan. It expressly excludes a range of supplemental or limited-benefit policies, including life care contracts, accident-only policies, specified disease policies, hospital indemnity policies, Medicare supplement policies, long-term care policies, and short-term major medical policies of six months or less, along with other supplemental policies identified by the Department of Commerce and Insurance.
Impact
This bill would add a new insurance coverage mandate in Chapter 376, RSMo, requiring most health carriers and health benefit plans to cover pediatric and adolescent obesity treatment beginning in 2027. It would affect insurers, health benefit plan administrators, and covered families by expanding mandated benefits and limiting cost-sharing for qualifying obesity-related care. The Department of Commerce and Insurance would retain authority to determine additional supplemental policies exempt from the mandate.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the available context suggests the measure is policy-driven and aimed at expanding access to medically recommended obesity treatment for children and young adults. The bill’s structure indicates support for evidence-based care and preventive intervention, but there is no direct record here of formal support or opposition from legislators or stakeholders. Because no votes or transcripts are provided, the overall sentiment cannot be measured from legislative debate, only inferred from the bill’s purpose.
Contention
The most likely points of contention are the scope and cost of the insurance mandate, especially the requirement to cover pharmacotherapy and bariatric surgery for minors and young adults, and the potential premium impact on insurers and policyholders. Another possible issue is the age range covered, the reliance on external clinical guidelines, and whether the mandate should apply broadly to all plans or be limited further. Exemptions for supplemental and short-term policies may also be debated, particularly by consumer advocates who may view them as too narrow or by insurers who may seek additional exclusions.